<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>米内网 | wechat-feeds</title><link>http://MjM5NzQ4MTg2MQ.favicon.privacyhide.com/favicon.ico</link><description>米内网是中国领先的集医药健康产业研究、医院市场研究、零售市场研究、商业渠道研究、互联网在线医药健康信息服务于一体的综合性专业信息服务平台。目前拥有七项数据分析技术获国家专利，每月收集数据3000多万条，有63个专业数据库为医药健康行业服务。</description><managingEditor> (hellodword)</managingEditor><pubDate>Tue, 27 Apr 2021 17:26:03 +0800</pubDate><image><url>http://MjM5NzQ4MTg2MQ.favicon.privacyhide.com/favicon.ico</url><title>米内网 | wechat-feeds</title><link>http://MjM5NzQ4MTg2MQ.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>27家江苏药企合揽1200亿！3家狂赚超20亿，22款1类新药、25个首仿上市可期</title><link>https://mp.weixin.qq.com/s/RXvaXHu7HSrqL8QpgDQ6Sw</link><description></description><content:encoded><![CDATA[27家江苏药企合揽1200亿！3家狂赚超20亿，22款1类新药、25个首仿上市可期]]></content:encoded><pubDate>Tue, 27 Apr 2021 16:14:50 +0800</pubDate></item><item><title>【重磅】40亿大品种扬子江将获批，巩固百亿市场龙头地位</title><link>https://mp.weixin.qq.com/s/m3WTNpBG3GOq5OYdWiRCJA</link><description></description><content:encoded><![CDATA[【重磅】40亿大品种扬子江将获批，巩固百亿市场龙头地位]]></content:encoded><pubDate>Tue, 27 Apr 2021 16:14:50 +0800</pubDate></item><item><title>【瞩目】齐鲁将拿下12亿抗抑郁药，4款新品来袭</title><link>https://mp.weixin.qq.com/s/ytc2w3E1y-2pwfpv8aSS6Q</link><description></description><content:encoded><![CDATA[【瞩目】齐鲁将拿下12亿抗抑郁药，4款新品来袭]]></content:encoded><pubDate>Tue, 27 Apr 2021 16:14:50 +0800</pubDate></item><item><title>【关注】最畅销的造影剂，恒瑞获得集采“入场券”</title><link>https://mp.weixin.qq.com/s/dB6Jr1OER-nl8iXKSr_9hw</link><description></description><content:encoded><![CDATA[【关注】最畅销的造影剂，恒瑞获得集采“入场券”]]></content:encoded><pubDate>Tue, 27 Apr 2021 16:14:50 +0800</pubDate></item><item><title>久等多年，头孢1类新药获批了！成都倍特再有注射剂过评，百亿市场大洗牌</title><link>https://mp.weixin.qq.com/s/uY-w3d_IeS10CI-Y82XaDA</link><description></description><content:encoded><![CDATA[久等多年，头孢1类新药获批了！成都倍特再有注射剂过评，百亿市场大洗牌]]></content:encoded><pubDate>Mon, 26 Apr 2021 16:11:46 +0800</pubDate></item><item><title>【深度】和黄药业总裁周俊杰：麝香保心丸重生成为中药名品之路</title><link>https://mp.weixin.qq.com/s/uGkr-IReB04hGgDRmxrX9g</link><description></description><content:encoded><![CDATA[【深度】和黄药业总裁周俊杰：麝香保心丸重生成为中药名品之路]]></content:encoded><pubDate>Mon, 26 Apr 2021 16:11:46 +0800</pubDate></item><item><title>【重磅】奥赛康抗肿瘤1类新药来了，PPI新药已在路上</title><link>https://mp.weixin.qq.com/s/RZpqv2tQTHiPhaMwNW6OcQ</link><description></description><content:encoded><![CDATA[【重磅】奥赛康抗肿瘤1类新药来了，PPI新药已在路上]]></content:encoded><pubDate>Mon, 26 Apr 2021 16:11:46 +0800</pubDate></item><item><title>【火爆】齐鲁再拿下注射剂首家过评，7个止吐药6个已过评</title><link>https://mp.weixin.qq.com/s/MOwM_84t4cYhdBrwFCSXEw</link><description></description><content:encoded><![CDATA[【火爆】齐鲁再拿下注射剂首家过评，7个止吐药6个已过评]]></content:encoded><pubDate>Mon, 26 Apr 2021 16:11:46 +0800</pubDate></item><item><title>康宁杰瑞：来到“后PD-1时代”，我们需要解决哪些问题？</title><link>https://mp.weixin.qq.com/s/OhlCb-XmsWakjx-WhxhKKA</link><description></description><content:encoded><![CDATA[康宁杰瑞：来到“后PD-1时代”，我们需要解决哪些问题？]]></content:encoded><pubDate>Sun, 25 Apr 2021 07:54:04 +0800</pubDate></item><item><title>科伦、齐鲁、东阳光药......102个新药获批临床！恒瑞抢攻$70亿市场，$38亿明星药获批</title><link>https://mp.weixin.qq.com/s/X6etUCUE-0fL7vzqvg0z1Q</link><description></description><content:encoded><![CDATA[科伦、齐鲁、东阳光药......102个新药获批临床！恒瑞抢攻$70亿市场，$38亿明星药获批]]></content:encoded><pubDate>Sun, 25 Apr 2021 07:54:04 +0800</pubDate></item><item><title>28家药企被重点监管，14个药挂网采购“叫停”！齐鲁、科伦……487个集采未中选药品调价</title><link>https://mp.weixin.qq.com/s/oTD52yo5UIz9GBm2AcgseA</link><description></description><content:encoded><![CDATA[28家药企被重点监管，14个药挂网采购“叫停”！齐鲁、科伦……487个集采未中选药品调价]]></content:encoded><pubDate>Sat, 24 Apr 2021 07:46:38 +0800</pubDate></item><item><title>厉害了！科伦15款1类新药、40个新品发力，49个品种过评，9个拟集采品种蓄势待发</title><link>https://mp.weixin.qq.com/s/lM1IYeiNH5vufhypTYomRg</link><description></description><content:encoded><![CDATA[厉害了！科伦15款1类新药、40个新品发力，49个品种过评，9个拟集采品种蓄势待发]]></content:encoded><pubDate>Fri, 23 Apr 2021 16:16:03 +0800</pubDate></item><item><title>【市场】60亿注射剂大品种，这家广东药企过评</title><link>https://mp.weixin.qq.com/s/kZKjS30ea-eO_OcoRIN3Kw</link><description></description><content:encoded><![CDATA[【市场】60亿注射剂大品种，这家广东药企过评]]></content:encoded><pubDate>Fri, 23 Apr 2021 16:16:03 +0800</pubDate></item><item><title>【瞩目】挑战辉瑞！豪森拿下$10亿品种首仿</title><link>https://mp.weixin.qq.com/s/3kRp8Wa_xvnBrpjfZJ7-tA</link><description></description><content:encoded><![CDATA[【瞩目】挑战辉瑞！豪森拿下$10亿品种首仿]]></content:encoded><pubDate>Fri, 23 Apr 2021 16:16:03 +0800</pubDate></item><item><title>【重磅】12亿降压药，上海医药首家过评</title><link>https://mp.weixin.qq.com/s/lzOI8HvgfR4Ac9fpyVgX5Q</link><description></description><content:encoded><![CDATA[【重磅】12亿降压药，上海医药首家过评]]></content:encoded><pubDate>Fri, 23 Apr 2021 16:16:03 +0800</pubDate></item><item><title>抗病毒龙头逆袭！东阳光药新添8个新药，31个产品备战集采，第五批再现弯道超车？</title><link>https://mp.weixin.qq.com/s/BdSdBb4nIk0gnxlK2m-2DQ</link><description></description><content:encoded><![CDATA[抗病毒龙头逆袭！东阳光药新添8个新药，31个产品备战集采，第五批再现弯道超车？]]></content:encoded><pubDate>Thu, 22 Apr 2021 16:34:44 +0800</pubDate></item><item><title>【重磅】石药、绿叶卖出超20亿！恒瑞猛攻这个领域，首个产品来了</title><link>https://mp.weixin.qq.com/s/HkQ1FM8AUN6IDAVlLI4ZEw</link><description></description><content:encoded><![CDATA[【重磅】石药、绿叶卖出超20亿！恒瑞猛攻这个领域，首个产品来了]]></content:encoded><pubDate>Thu, 22 Apr 2021 16:34:44 +0800</pubDate></item><item><title>【热议】扬子江抢首仿！剑指拜耳暴涨1150%的抗肿瘤药</title><link>https://mp.weixin.qq.com/s/lvDKl-q8sKb0CODVfhjfCg</link><description></description><content:encoded><![CDATA[【热议】扬子江抢首仿！剑指拜耳暴涨1150%的抗肿瘤药]]></content:encoded><pubDate>Thu, 22 Apr 2021 16:34:44 +0800</pubDate></item><item><title>​【火热】“万能靶向药”再迎挑战者，豪森、奥赛康已抢先入局</title><link>https://mp.weixin.qq.com/s/8_QNpHr98BqkEfJcxx35MA</link><description></description><content:encoded><![CDATA[​【火热】“万能靶向药”再迎挑战者，豪森、奥赛康已抢先入局]]></content:encoded><pubDate>Thu, 22 Apr 2021 16:34:44 +0800</pubDate></item><item><title>华东医药蜕变！11款新药、6个新品出击，集采失标品种销量不减，猛攻慢病药、医美</title><link>https://mp.weixin.qq.com/s/MiywQdLBFuY9LjS3oRY3FQ</link><description></description><content:encoded><![CDATA[华东医药蜕变！11款新药、6个新品出击，集采失标品种销量不减，猛攻慢病药、医美]]></content:encoded><pubDate>Wed, 21 Apr 2021 16:29:06 +0800</pubDate></item></channel></rss>